Research map: Interpretation of the BRIGHT-2 Trial

Back to the article

Papers in this map

  1. Immortal Time Bias in Pharmacoepidemiology · Samy Suissa · 2007 · 1793 citations · Cited by this paper
  2. Considerations in Genomic Therapy Matching—Reply · 2026 · Related
  3. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 · George W. Sledge · 2019 · 1014 citations · Cited by this paper
  4. Survival Language · 2026 · Related
  5. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer · Dennis J. Slamon · 2019 · 874 citations · Cited by this paper
  6. A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0 · 2026 · Related
  7. Landmark Analysis at the 25-Year Landmark Point · Urania G. Dafni · 2011 · 571 citations · Cited by this paper
  8. Global Consensus on the Management of Primary Localized Chordoma · 2026 · Related
  9. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression · Jiayu Wang · 2026 · 4 citations · Cited by this paper
  10. Survival in the SONIA Trial—Reply · 2026 · Related
  11. When TNM Staging Is Not Sufficient · 2026 · Related
  12. Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma · 2026 · Related
  13. Treatment Delays in Early Age–Onset Colorectal Cancer · 2026 · Related
  14. Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply · 2026 · Related
  15. Error in Open Access License · 2026 · Related

Source: OpenAlex (CC0)